• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.

作者信息

Schwartz Candice, Pfanzelter Nicklas, Kuzel Timothy M

机构信息

Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

Division of Hematology/Oncology/Cell Therapy, Department of Internal Medicine, Rush University Medical Center, Chicago, IL.

出版信息

Clin Genitourin Cancer. 2017 Oct;15(5):e903-e906. doi: 10.1016/j.clgc.2017.05.017. Epub 2017 May 25.

DOI:10.1016/j.clgc.2017.05.017
PMID:28624319
Abstract
摘要

相似文献

1
The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.乐伐替尼与依维莫司治疗嫌色细胞型非透明细胞肾细胞癌的疗效：一例报告及文献综述
Clin Genitourin Cancer. 2017 Oct;15(5):e903-e906. doi: 10.1016/j.clgc.2017.05.017. Epub 2017 May 25.
2
Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.在转移性肾细胞癌中，乐伐替尼/依维莫司联合用药比单独使用依维莫司更能提高生存率。
Clin Adv Hematol Oncol. 2015 Aug;13(8):512-3.
3
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.乐伐替尼和依维莫司治疗转移性肾细胞癌引起的高血压
Int J Mol Sci. 2017 Aug 10;18(8):1736. doi: 10.3390/ijms18081736.
4
Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.乐伐替尼治疗晚期肾细胞癌患者。
Future Oncol. 2016 Oct;12(19):2195-204. doi: 10.2217/fon-2016-0215. Epub 2016 Jun 24.
5
Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.间接治疗比较包括网络荟萃分析：仑伐替尼联合依维莫司用于晚期/转移性肾细胞癌的二线治疗。
PLoS One. 2019 Mar 5;14(3):e0212899. doi: 10.1371/journal.pone.0212899. eCollection 2019.
6
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.仑伐替尼联合依维莫司或帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌的研究设计与理论基础。
Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.
7
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.乐伐替尼联合依维莫司治疗一例多次治疗的乳头状肾细胞癌患者的疗效：病例报告
Tumori. 2020 Dec;106(6):NP79-NP83. doi: 10.1177/0300891620924472. Epub 2020 May 27.
8
Lenvatinib for the treatment of kidney cancer.仑伐替尼治疗肾癌。
Expert Rev Anticancer Ther. 2018 Jun;18(6):511-518. doi: 10.1080/14737140.2018.1470506. Epub 2018 May 8.
9
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.乐伐替尼联合依维莫司治疗转移性肾细胞癌的独立评估
Lancet Oncol. 2016 Jan;17(1):e4-5. doi: 10.1016/S1470-2045(15)00543-4. Epub 2015 Dec 23.
10
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC.一线帕博利珠单抗联合乐伐替尼治疗非透明细胞肾细胞癌有效。
Nat Rev Clin Oncol. 2023 Oct;20(10):661. doi: 10.1038/s41571-023-00809-3.

引用本文的文献

1
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.评估乐伐替尼和依维莫司治疗晚期肾细胞癌的有效性和安全性：来自RELIEVE研究对经大量预处理患者分析的见解。
Ther Adv Urol. 2024 Apr 17;16:17562872241244574. doi: 10.1177/17562872241244574. eCollection 2024 Jan-Dec.
2
An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases.肾细胞癌全身靶向治疗概述，重点关注转移性肾细胞癌和脑转移
Curr Issues Mol Biol. 2023 Sep 21;45(9):7680-7704. doi: 10.3390/cimb45090485.
3
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
晚期非透明细胞肾细胞癌中的免疫检查点抑制：将透明细胞组织学的成功经验转化为新机遇。
Cancers (Basel). 2021 Jul 21;13(15):3652. doi: 10.3390/cancers13153652.